

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :	C12N 15/52, 15/54, 15/70, 1/21, C08G 63/06, C12P 7/62	A2	(11) International Publication Number: WO 99/61624 (43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number:	PCT/US99/11417		(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date:	21 May 1999 (21.05.99)		
(30) Priority Data:	60/086,396 22 May 1998 (22.05.98)	US	Published <i>Without international search report and to be republished upon receipt of that report.</i>
(71) Applicant:	METABOLIX, INC. [US/US]; 303 Third Street, Cambridge, MA 02142 (US).		
(72) Inventors:	SKRALY, Frank, A.; Apartment 5, 39 Bay State Road, Boston, MA 02215 (US). PEOPLES, Oliver, P.; 27 Radcliffe Road, Arlington, MA 02474 (US).		
(74) Agent:	PABST, Patrea, L.; Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).		

(54) Title: POLYHYDROXYALKANOATE BIOPOLYMER COMPOSITIONS



Pathways from levulinic acid to poly-4-hydroxyvalerate.

(57) Abstract

Several novel PHA polymer compositions produced using biological systems include monomers such as 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate and 5-hydroxyvalerate. These PHA compositions can readily be extended to incorporate additional monomers including, for example, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate or other longer chain 3-hydroxyacids containing seven or more carbons. This can be accomplished by taking natural PHA producers and mutating through chemical or transposon mutagenesis to delete or inactivate genes encoding undesirable activities. Alternatively, the strains can be genetically engineered to express only those enzymes required for the production of the desired polymer composition. Methods for genetically engineering PHA producing microbes are widely known in the art (Huisman and Madison, 1998, Microbiology and Molecular Biology Reviews, 63: 21-53). These polymers have a variety of uses in medical, industrial and other commercial areas.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

POLYHYDROXYALKANOATE BIOPOLYMER COMPOSITIONS**Background to the Invention**

5 This application claims priority to U.S. Serial No. 60/086,396 filed
May 22, 1998.

Numerous microorganisms have the ability to accumulate intracellular reserves of PHA polymers. Poly [(R)-3-hydroxyalkanoates] (PHAs) are biodegradable and biocompatible thermoplastic materials, produced from
10 renewable resources, with a broad range of industrial and biomedical applications (Williams and Peoples, 1996, CHEMTECH 26, 38-44). Around 100 different monomers have been incorporated into PHA polymers, as reported in the literature (Steinbüchel and Valentin, 1995, FEMS Microbiol. Lett. 128; 219-228) and the biology and genetics of their metabolism has
15 recently been reviewed (Huisman and Madison, 1998, Microbiology and Molecular Biology Reviews, 63: 21-53).

To date, PHAs have seen limited commercial availability, with only the copolymer poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) being available in development quantities. This copolymer has been produced by
20 fermentation of the bacterium *Ralstonia eutropha*. Fermentation and recovery processes for other PHA types have also been developed using a range of bacteria including *Azotobacter*, *Alcaligenes latus*, *Comamonas testosterone* and genetically engineered *E. coli* and *Klebsiella* and have recently been reviewed (Braunegg et al., 1998, Journal of Biotechnology 65:
25 127-161; Choi and Lee, 1999, Appl. Microbiol. Biotechnol. 51: 13-21). More traditional polymer synthesis approaches have also been examined, including direct condensation and ring-opening polymerization of the corresponding lactones (Jesudason and Marchessault, 1994, Macromolecules 27: 2595-2602).

30 Synthesis of PHA polymers containing the monomer 4-hydroxybutyrate (PHB4HB, Doi, Y. 1995, Macromol. Symp. 98, 585-599) or 4-hydroxyvalerate and 4-hydroxyhexanoate containing PHA polyesters have been described (Valentin et al., 1992, Appl. Microbiol. Biotechnol. 36, 507-

514 and Valentin et al., 1994, *Appl. Microbiol. Biotechnol.* 40, 710-716). These polyesters have been manufactured using methods similar to that originally described for PHBV in which the microorganisms are fed a relatively expensive non-carbohydrate feedstock in order to force the incorporation of the monomer into the PHA polyester. The PHB4HB copolymers can be produced with a range of monomer compositions which again provides a range of polymer (Saito, Y, Nakamura, S., Hiramitsu, M. and Doi, Y., 1996, *Polym. Int.* 39: 169).

PHA copolymers of 3-hydroxybutyrate-co-3-hydroxypropionate have also been described (Shimamura et. al., 1994, *Macromolecules* 27: 4429-4435; Cao et. al., 1997, *Macromol. Chem. Phys.* 198: 3539-3557). The highest level of 3-hydroxypropionate incorporated into these copolymers 88 mol % (Shimamura et. al., 1994, *Macromolecules* 27: 4429-4435).

PHA terpolymers containing 4-hydroxyvalerate have been produced by feeding a genetically engineered *Pseudomonas putida* strain on 4-hydroxyvalerate or levulinic acid which resulted in a three component PHA, Poly(3-hydroxybutyrate-co-3-hydroxyvalerate-4-hydroxyvalerate) (Valentin et. al., 1992, *Appl. Microbiol. Biotechnol.* 36: 507-514; Steinbüchel and Gorenflo, 1997, *Macromol. Symp.* 123: 61-66). It is desirable to develop biological systems to produce two component polymers comprising 4-hydroxyvalerate or poly(4-hydroxyvalerate) homopolymer. The results of Steinbüchel and Gorenflo (1997, *Macromol. Symp.* 123: 61-66) indicate that *Pseudomonas putida* has the ability to convert levulinic acid to 4-hydroxyvalerate.

Hein et al. (1997) attempted to synthesize poly-4HV using transgenic *Escherichia coli* strain XL1-Blue but were unsuccessful. These cells carried a plasmid which permitted expression of the *A. eutrophus* PHA synthase and the *Clostridium kluyveri* 4-hydroxybutyryl-CoA transferase genes. When the transgenic *E. coli* were fed 4HV, α -valerolactone, or levulinic acid, they produced only a small amount of PHB homopolymer.

It is clearly desirable for industrial reasons to be able to produce a range of defined PHA homopolymer, copolymer and terpolymer compositions. To accomplish this, it is desirable to be able to control the availability of the individual enzymes in the corresponding PHA biosynthetic pathways.

It is therefore an object of the present invention to provide a range of defined PHA homopolymer, copolyer and terpolymer compositions.

It is another object of the present invention to provide a method and materials to control the availability of the individual enzymes in the corresponding PHA biosynthetic pathways.

Summary of the Invention

Several novel PHA polymer compositions produced using biological systems include monomers such as 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate and 5-hydroxyvalerate. These PHA compositions can readily be extended to incorporate additional monomers including, for example, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate or other longer chain 3-hydroxyacids containing seven or more carbons. This can be accomplished by taking natural PHA producers and mutating through chemical or transposon mutagenesis to delete or inactivate genes encoding undesirable activities. Alternatively, the strains can be genetically engineered to express only those enzymes required for the production of the desired polymer composition. Methods for genetically engineering PHA producing microbes are widely known in the art (Huisman and Madison, 1998, *Microbiology and Molecular Biology Reviews*, 63: 21-53). These polymers have a variety of uses in medical, industrial and other commercial areas.

Brief Description of the Drawings

Figure 1 is a schematic of the pathway from levulinic acid to poly-4-hydroxyvalerate.

Figure 2 is a schematic of a construct of plasmid pFS16, which includes the lacI (inducer) gene, ampicillin resistance gene, and hbcT gene.

Figure 3 is a schematic of a construct of plasmid pFS30, which includes the lacI (inducer) gene, ampicillin resistance gene, polyhydroxyalkanoate polymerase (phaC) gene, and hbcT gene.

Detailed Description of the Invention

Several novel PHA polymer compositions have been produced using biological systems to incorporate monomers such as 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate and 5-hydroxyvalerate. These PHA compositions can readily be extended to incorporate additional monomers including, for example, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate or other longer chain 3-hydroxyacids containing seven or more carbons. Techniques and procedures to engineer transgenic organisms that synthesize PHAs containing one or more of these monomers either as sole constituent or as co-monomer have been developed. In these systems the transgenic organism is either a bacterium eg. *Escherichia coli*, *K. pneumoniae*, *Ralstonia eutropha* (formerly *Alcaligenes eutrophus*), *Alcaligenes latus* or other microorganisms able to synthesize PHAs, or a higher plant or plant component, such as the seed of an oil crop (*Brassica*, sunflower, soybean, corn, safflower, flax, palm or coconut or starch accumulating plants (potato, tapioca, cassava).

It is crucial for efficient PHA synthesis in recombinant *E. coli* strains that the expression of all the genes involved in the pathway be adequate. To this end, the genes of interest can be expressed from extrachromosomal DNA molecules such as plasmids, which intrinsically results in a copy number effect and consequently high expression levels, or, more preferably, they can be expressed from the chromosome. For large scale fermentations of commodity type products it is generally known that plasmid-based systems are unsatisfactory due to the extra burden of maintaining the plasmids and the problems of stable expression. These drawbacks can be overcome using chromosomally encoded enzymes by improving the transcriptional and translational signals preceding the gene of interest such that expression is sufficient and stable.

The biological systems must express one or more enzymes as required to convert the monomers into polymers. Suitable substrates include 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate, 5-hydroxyvalerate, 3-

hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate and other longer chain 3-hydroxyacids containing seven or more carbons. These enzymes include polyhydroxyalkanoate synthase, acyl-CoA transferase and hydroxyacyl CoA transferase, and hydroxyacyl CoA synthetase. These 5 enzymes can be used with these substrates to produce in a biological system such as bacteria, yeast, fungi, or plants, polymer such as poly(3-hydroxybutyrate-co-4-hydroxyvalerate), poly(4-hydroxyvalerate), poly(3-hydroxypropionate-co-5-hydroxyvalerate), poly(2-hydroxybutyrate), poly(2-hydroxybutyrate-co-3-hydroxybutyrate), and poly(3-hydroxypropionate).

10 Genes encoding the required enzymes can be acquired from multiple sources. U.S. Patent Nos. 5,798,235 and 5,534,432 to Peoples, et al., describe polyhydroxyalkanoate synthetase, reductase and thiolase. A 4-hydroxybutyryl CoA transferase gene from *C. aminobutyricum* is described by Willadsen and Buckel, FEMS Microbiol. Lett. (1990) 70: 187-192) or 15 from *C. kluveri* is described by Söhling and Gottschalk, 1996, J. Bacteriol. 178, 871-880). An acyl coenzyme A synthetase from *Neurospora crassa* is described by Hii and Courtright, J. Bacteriol. 1982.150(2), 981-983. A hydroxyacyl transferase from Clostridium is described by Hofmeister and Bucker, Eur. J. Biochem. 1992, 206(2), 547-552.

20 It is important for efficient PHA production that strains do not lose the capability to synthesize the biopolymer for the duration of the inoculum train and the production run. Loss of any of the *pha* genes results in loss of product. Both are undesirable and stable propagation of the strain is therefore required. Merely integrating the gene encoding the transferase or 25 synthase may not result in significant polymer production. Enzyme expression can be enhanced through alteration of the promoter region or mutagenesis or other known techniques, followed by screening for polymer production. Growth and morphology of these recombinant PHA producers is not compromised by the presence of *pha* genes on the chromosome.

30 The present invention will be further understood by reference to the following non-limiting examples.

hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate and other longer chain 3-hydroxyacids containing seven or more carbons. These enzymes include polyhydroxyalkanoate synthase, acyl-CoA transferase and hydroxyacyl CoA transferase, and hydroxyacyl CoA synthetase. These 5 enzymes can be used with these substrates to produce in a biological system such as bacteria, yeast, fungi, or plants, polymer such as poly(3-hydroxybutyrate-co-4-hydroxyvalerate), poly(4-hydroxyvalerate), poly(3-hydroxypropionate-co-5-hydroxyvalerate), poly(2-hydroxybutyrate), poly(2-hydroxybutyrate-co-3-hydroxybutyrate), and poly(3-hydroxypropionate).

10 Genes encoding the required enzymes can be acquired from multiple sources. U.S. Patent Nos. 5,798,235 and 5,534,432 to Peoples, et al., describe polyhydroxyalkanoate synthetase, reductase and thiolase. A 4-hydroxybutyryl CoA transferase gene from *C. aminobutyricum* is described by Willadsen and Buckel, FEMS Microbiol. Lett. (1990) 70: 187-192) or 15 from *C. kluyveri* is described by Söhling and Gottschalk, 1996, J. Bacteriol. 178, 871-880). An acyl coenzyme A synthetase from *Neurospora crassa* is described by Hii and Courtright, J. Bacteriol. 1982.150(2), 981-983. A hydroxyacyl transferase from Clostridium is described by Hofmeister and Bucker, Eur. J. Biochem. 1992, 206(2), 547-552.

20 It is important for efficient PHA production that strains do not lose the capability to synthesize the biopolymer for the duration of the inoculum train and the production run. Loss of any of the *pha* genes results in loss of product. Both are undesirable and stable propagation of the strain is therefore required. Merely integrating the gene encoding the transferase or 25 synthase may not result in significant polymer production. Enzyme expression can be enhanced through alteration of the promoter region or mutagenesis or other known techniques, followed by screening for polymer production. Growth and morphology of these recombinant PHA producers is not compromised by the presence of *pha* genes on the chromosome.

30 The present invention will be further understood by reference to the following non-limiting examples.

Example 1. Poly(3HB-co-4HV) from 4-hydroxyvalerate and glucose in *E. coli*.

Construction of pFS16.

The plasmid pTrcN is a derivative of pTrc99a (Pharmacia; Uppsala, Sweden);
5 the modification that distinguishes pTrcN is the removal of the *NcoI* restriction site by digestion with *NcoI*, treatment with T4 DNA polymerase, and self-ligation. The *orfZ* gene encoding the 4-hydroxybutyryl-CoA transferase from *Clostridium kluyveri* was amplified using the polymerase chain reaction (PCR) and a kit from Perkin Elmer (Foster City, CA) using plasmid pCK3 (Söhling and Gottschalk, 1996, J. Bacteriol. 10 178: 871-880) as the target DNA and the following oligonucleotide primers:
10 5' –
TCCCCCTAGGATTCAAGGAGGTTTTATGGAGTGGGAAGAGATATAAAG
– 3'
(*orfZ* 5' *AvrII*)
15 5' – CCTTAAGTCGACAAATTCTAAAATCTCTTTAAATTC – 3'
(*orfZ* 3' *SalI*)

The resulting PCR product was digested with *AvrII* and *SalI* and
20 ligated to pTrcN that had been digested with *XbaI* (which is compatible with *AvrII*) and *SalI* to form plasmid pFS16 such that the 4-hydroxybutyryl-CoA transferase can be expressed from the IPTG (isopropyl-β-D-glucopyranoside)
- inducible *trc* promoter.

Construction of pFS30.

25 The plasmid pFS30 was derived from pFS16 by adding the *Ralstonia eutropha* PHA synthase (*phaC*) gene (Peoples and Sinskey, 1989, J. Biol. Chem. 264:15298-15303) which had been modified by the addition of a strong *E. coli* ribosome binding site as described by (Gerngross et. al., 1994, Biochemistry 33: 9311-9320). The plasmid pAeT414 was digested with
30 *XmaI* and *StuI* so that the *R. eutropha* promoter and the structural *phaC* gene were present on one fragment. pFS16 was cut with *BamHI*, treated with T4 DNA polymerase to create blunt ends, then digested with *XmaI*. The two DNA fragments thus obtained were ligated together to form pFS30. In this

Example 1. Poly(3HB-co-4HV) from 4-hydroxyvalerate and glucose in *E. coli*.

Construction of pFS16.

The plasmid pTrcN is a derivative of pTrc99a (Pharmacia; Uppsala, Sweden);
5 the modification that distinguishes pTrcN is the removal of the *NcoI* restriction site
by digestion with *NcoI*, treatment with T4 DNA polymerase, and self-ligation. The
orfZ gene encoding the 4-hydroxybutyryl-CoA transferase from *Clostridium kluyveri*
was amplified using the polymerase chain reaction (PCR) and a kit from Perkin Elmer
(Foster City, CA) using plasmid pCK3 (Söhling and Gottschalk, 1996, J. Bacteriol.
10 178: 871-880) as the target DNA and the following oligonucleotide primers:
5' –
TCCCTAGGATTCAAGGAGGTTTTATGGAGTGGGAAGAGATATAAAG
– 3'
(*orfZ* 5' *AvrII*)
15 5' – CCTTAAGTCGACAAATTCTAAAATCTCTTTAAATTC – 3'
(*orfZ* 3' *SalI*)

The resulting PCR product was digested with *AvrII* and *SalI* and
20 ligated to pTrcN that had been digested with *XbaI* (which is compatible with
AvrII) and *SalI* to form plasmid pFS16 such that the 4-hydroxybutyryl-CoA
transferase can be expressed from the IPTG (isopropyl-β-D-glucopyranoside)
- inducible *trc* promoter.

Construction of pFS30.

25 The plasmid pFS30 was derived from pFS16 by adding the *Ralstonia eutropha* PHA synthase (*phaC*) gene (Peoples and Sinskey, 1989, J. Biol. Chem. 264:15298-15303) which had been modified by the addition of a strong *E. coli* ribosome binding site as described by (Gerngross et. al., 1994, Biochemistry 33: 9311-9320). The plasmid pAeT414 was digested with
30 *XmaI* and *StuI* so that the *R. eutropha* promoter and the structural *phaC* gene were present on one fragment. pFS16 was cut with *BamHI*, treated with T4 DNA polymerase to create blunt ends, then digested with *XmaI*. The two DNA fragments thus obtained were ligated together to form pFS30. In this

construct the PHB synthase and 4-hydroxybutyryl-CoA transferase are expressed from the *A. eutrophus* phbC promoter (Peoples and Sinskey, 1989. J. Biol. Chem. 264:15298-15303). Other suitable plasmids expressing PHB synthase and 4-hydroxybutyryl-CoA transferase have been described (Hein et. al., 1997, FEMS Microbiol. Lett. 153: 411-418; Valentin and Dennis, 1997, J. Biotechnol. 58:33-38).

E. coli MBX769 has a PHA synthase integrated into its chromosome. This strain is capable of synthesizing poly(3-hydroxybutyrate) (PHB) from glucose with no extrachromosomal genes present. MBX769 is also deficient in *fadR*, the repressor of the fatty-acid-degradation pathway and effector of many other cellular functions, it is deficient in *rpoS*, a regulator of stationary-phase gene expression, and it is deficient in *atoA*, one subunit of the acetoacetyl-CoA transferase. MBX769 also expresses *atoC*, a positive regulator of the acetoacetate system, constitutively.

E. coli MBX769 carrying the plasmid pFS16 (Figure 2), which permitted the expression of the *Clostridium kluyveri* 4-hydroxybutyryl-CoA transferase, was precultured at 37 °C in 100 mL of LB medium containing 100 µg/mL sodium ampicillin in a 250-mL Erlenmeyer flask with shaking at 200 rpm. The cells were centrifuged at 5000g for 10 minutes to remove them from the LB medium after 16 hours, and they were resuspended in 100 mL of a medium containing, per liter: 4.1 or 20 12.4 g sodium 4-hydroxyvalerate (4HV); 5 g/L sodium 4-hydroxybutyrate (4HB); 2 g glucose; 2.5 g LB broth powder (Difco; Detroit, Mich.); 50 mmol potassium phosphate, pH 7; 100 µg/mL sodium ampicillin; and 0.1 mmol isopropyl-β-D-thiogalactopyranoside (IPTG). The sodium 4-hydroxyvalerate was obtained by saponification of γ-valerolactone in a solution of sodium hydroxide. The cells were 25 incubated in this medium for 3 days with shaking at 200 rpm at 32 °C in the same flask in which they had been precultured. When 4.1 g/L sodium 4-hydroxyvalerate was present initially, the cells accumulated a polymer to 52.6% of the dry cell weight that consisted of 63.4% 3HB units and 36.6% 4HB units but no 4HV units.

When 12.4 g/L sodium 4HV was present initially, the cells accumulated a polymer to 45.9% of the dry cell weight that consisted of 95.5% 3HB units and 4.5% 30 4HV units but no detectable 4HB units. The identity of the PHB-co-4HV polymer was verified by nuclear magnetic resonance (NMR) analysis of the solid product obtained by chloroform extraction of whole cells followed by filtration, ethanol

construct the PHB synthase and 4-hydroxybutyryl-CoA transferase are expressed from the *A. eutrophus* phbC promoter (Peoples and Sinskey, 1989. J. Biol. Chem. 264:15298-15303). Other suitable plasmids expressing PHB synthase and 4-hydroxybutyryl-CoA transferase have been described (Hein et. al., 1997, FEMS Microbiol. Lett. 153: 411-418; Valentin and Dennis, 1997, J. Biotechnol. 58:33-38).

E. coli MBX769 has a PHA synthase integrated into its chromosome. This strain is capable of synthesizing poly(3-hydroxybutyrate) (PHB) from glucose with no extrachromosomal genes present. MBX769 is also deficient in *fadR*, the repressor of the fatty-acid-degradation pathway and effector of many other cellular functions, it is deficient in *rpoS*, a regulator of stationary-phase gene expression, and it is deficient in *atoA*, one subunit of the acetoacetyl-CoA transferase. MBX769 also expresses *atoC*, a positive regulator of the acetoacetate system, constitutively.

E. coli MBX769 carrying the plasmid pFS16 (Figure 2), which permitted the expression of the *Clostridium kluyveri* 4-hydroxybutyryl-CoA transferase, was precultured at 37 °C in 100 mL of LB medium containing 100 µg/mL sodium ampicillin in a 250-mL Erlenmeyer flask with shaking at 200 rpm. The cells were centrifuged at 5000g for 10 minutes to remove them from the LB medium after 16 hours, and they were resuspended in 100 mL of a medium containing, per liter: 4.1 or 12.4 g sodium 4-hydroxyvalerate (4HV); 5 g/L sodium 4-hydroxybutyrate (4HB); 2 g glucose; 2.5 g LB broth powder (Difco; Detroit, Mich.); 50 mmol potassium phosphate, pH 7; 100 µg/mL sodium ampicillin; and 0.1 mmol isopropyl-β-D-thiogalactopyranoside (IPTG). The sodium 4-hydroxyvalerate was obtained by saponification of γ-valerolactone in a solution of sodium hydroxide. The cells were incubated in this medium for 3 days with shaking at 200 rpm at 32 °C in the same flask in which they had been precultured. When 4.1 g/L sodium 4-hydroxyvalerate was present initially, the cells accumulated a polymer to 52.6% of the dry cell weight that consisted of 63.4% 3HB units and 36.6% 4HB units but no 4HV units.

When 12.4 g/L sodium 4HV was present initially, the cells accumulated a polymer to 45.9% of the dry cell weight that consisted of 95.5% 3HB units and 4.5% 4HV units but no detectable 4HB units. The identity of the PHB-co-4HV polymer was verified by nuclear magnetic resonance (NMR) analysis of the solid product obtained by chloroform extraction of whole cells followed by filtration, ethanol

Example 3. Poly(3HB-co-2HB) from 2-hydroxybutyrate and glucose in *E. coli*.

E. coli MBX769 carrying the plasmid pFS16 was precultured at 37 °C in 100 mL of LB medium containing 100 µg/mL sodium ampicillin in a 250-mL Erlenmeyer flask with shaking at 200 rpm. The cells were centrifuged at 5000g for 10 minutes to remove them from the LB medium after 16 hours, and they were resuspended in 100 mL of a medium containing, per liter: 5 g sodium 2-hydroxybutyrate (2HB); 2 g glucose; 2.5 g LB broth powder; 50 mmol potassium phosphate, pH 7; 100 µg/mL sodium ampicillin; and 0.1 mmol IPTG. The cells were incubated in this medium for 10 days with shaking at 150 rpm at 33 °C in the same flask in which they had been precultured. The cells accumulated a polymer to 19.0% of the dry cell weight that consisted of 99.7% 3HB units and 0.3% 2HB units. The identity of the poly(3HB-co-2HB) polymer was verified by GC analysis of the solid product obtained by chloroform extraction of whole cells followed by filtration, ethanol precipitation of the polymer from the filtrate, and washing of the polymer with water. It was also verified by GC analysis of whole cells that had been washed with water and propanolyzed in a mixture of 50% 1,2-dichloroethane, 40% 1-propanol, and 10% concentrated hydrochloric acid at 100 °C for 5 hours, with PHB and sodium 2-hydroxybutyrate as the standards.

Example 4. Poly(2HB) from 2-hydroxybutyrate in *E. coli*.

Escherichia coli MBX184 is not capable of synthesizing poly(3-hydroxybutyrate) (PHB) from glucose. MBX184 is deficient in *fadR* and expresses *atoC* constitutively.

MBX184 carrying the plasmid pFS30 was precultured at 37 °C in 100 mL of LB medium containing 100 µg/mL sodium ampicillin. The cells were centrifuged at 5000g for 10 minutes to remove them from the LB medium after 16 hours, and they were resuspended in 100 mL of a medium containing, per liter: 5 g sodium 2-hydroxybutyrate (2HB); 2 g glucose; 2.5 g LB broth powder; 50 mmol potassium phosphate, pH 7; 100 µg/mL sodium ampicillin; and 0.1 mmol IPTG. The cells were incubated in this medium for 3 days with shaking at 150 rpm at 33 °C in the same flask in which they had been precultured.

The cells accumulated a polymer to 1.0% of the dry cell weight that consisted of 100% 2HB units. The identity of the poly(2HB) polymer was verified by GC

analysis of whole cells that had been washed with water and propanolyzed in a mixture of 50% 1,2-dichloroethane, 40% 1-propanol, and 10% concentrated hydrochloric acid at 100 °C for 5 hours, with sodium 2-hydroxybutyrate as the standard.

5 **Example 5. Poly-3HP and poly-3HP-co-5HV from 1,3-propanediol and from 1,5-pentanediol.**

Escherichia coli MBX184 carrying the plasmid pFS30 was precultured at 37 °C in 100 mL of LB medium containing 100 µg/mL sodium ampicillin. The cells were centrifuged at 5000g for 10 minutes to remove them from the LB medium after 16 hours, and they were resuspended in 100 mL of a medium containing, per liter: 10 g 1,3-propanediol (1,3-PD) or 1,5-pentanediol (1,5-PD); 2 g glucose; 2.5 g LB broth powder; 50 mmol potassium phosphate, pH 7; 100 µg/mL sodium ampicillin; and 0.1 mmol IPTG. The cells were incubated in this medium for 3 days with shaking at 200 rpm at 30 °C in the same flask in which they had been precultured. When the diol substrate was 1,3-PD, the cells accumulated a polymer to 7.0% of the dry cell weight that consisted entirely of 3HP units. When the substrate was 1,5-PD, the cells accumulated a polymer to 22.1% of the dry cell weight that consisted of greater than 90% 3-hydroxypropionate units and less than 10% 5-hydroxyvalerate units. The identity of the poly(3-hydroxypropionate) polymer was verified by NMR analysis of the solid product obtained by sodium hypochlorite extraction of whole cells followed by centrifugation and washing of the polymer with water. The identity of both polymers was verified by GC analysis of sodium hypochlorite-extracted polymer that was propanolyzed in a mixture of 50% 1,2-dichloroethane, 40% 1-propanol, and 10% concentrated hydrochloric acid at 100 °C for 5 hours, with β-propiolactone and δ-valerolactone as the standards.

10 **Example 6. Poly-5HV from 5-hydroxyvaleric acid.**

Escherichia coli MBX1177 carrying the plasmid pFS30 was precultured at 37 °C in 50 mL of LB medium containing 100 µg/mL sodium ampicillin. The cells were centrifuged at 5000g for 10 minutes to remove them from the LB medium after 8 hours, and they were resuspended in 100 mL of a medium containing, per liter: 10 g sodium 5-hydroxyvalerate (5HV); 5 g glucose; 2.5 g LB broth powder; 50 mmol potassium phosphate, pH 7; 100 µg/mL sodium ampicillin; and 0.1 mmol IPTG. The sodium 5HV was obtained by saponification of d-valerolactone. The cells were

incubated in this medium for 3 days with shaking at 200 rpm at 30 °C in the same flask in which they had been precultured. GC analysis was conducted with lyophilized whole cells that were butanolized in a mixture of 90% 1-butanol and 10% concentrated hydrochloric acid at 110 °C for 5 hours; the standard was sodium 5-hydroxyvalerate. This analysis showed that the cells had accumulated poly(5HV) to 13.9% of the dry cell weight. The identity of the poly(5-hydroxyvalerate) polymer was verified by NMR analysis of the solid product obtained by 1,2-dichloroethane extraction of whole cells followed by centrifugation and washing of the polymer with water.

10

incubated in this medium for 3 days with shaking at 200 rpm at 30 °C in the same flask in which they had been precultured. GC analysis was conducted with lyophilized whole cells that were butanolized in a mixture of 90% 1-butanol and 10% concentrated hydrochloric acid at 110 °C for 5 hours; the standard was sodium 5-hydroxyvalerate. This analysis showed that the cells had accumulated poly(5HV) to 13.9% of the dry cell weight. The identity of the poly(5-hydroxyvalerate) polymer was verified by NMR analysis of the solid product obtained by 1,2-dichloroethane extraction of whole cells followed by centrifugation and washing of the polymer with water.

10

We claim:

1. A polymer produced by providing one or more substrates selected from the group consisting of 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate, 5-hydroxyvalerate, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate and other longer chain 3-hydroxyacids containing seven or more carbons,

wherein the biological system expresses enzymes selected from the group consisting polyhydroxyalkanoate synthase, acyl-CoA transferase, hydroxyacyl CoA transferase, and hydroxyacyl CoA synthetase such that the polymers accumulate.

2. The polymer of claim 1 selected from the group consisting of poly(3-hydroxybutyrate-co-4-hydroxyvalerate), poly(4-hydroxyvalerate), poly(3-hydroxypropionate-co-5-hydroxyvalerate), poly(2-hydroxybutyrate), poly(2-hydroxybutyrate-co-3-hydroxybutyrate), poly(3-hydroxypropionate), produced in a biological system selected from the group comprising bacteria, yeasts, fungi and plants, wherein the biological system expresses enzymes selected from the group consisting polyhydroxyalkanoate synthase, acyl-CoA transferase and hydroxyacyl CoA transferase, and hydroxyacyl CoA synthetase such that the polymers accumulate in the presence of appropriate substrates.

3. The polymer of claim 1 wherein the polymer is poly(3-hydroxybutyrate-co-4-hydroxyvalerate).

4. The polymer of claim 1 wherein the polymer is poly(4-hydroxyvalerate).

5. The polymer of claim 1 wherein the polymer is poly(3-hydroxypropionate-co-5-hydroxyvalerate).

6. The polymer of claim 1 wherein the polymer is poly(3-hydroxypropionate).

7. A polyhydroxyalkanoate polymer comprising 2-hydroxybutyrate as a comonomer, wherein the polymer is produced in a biological system selected from the group comprising bacteria, yeasts, fungi and plants, wherein the biological system expresses enzymes selected from the

We claim:

1. A polymer produced by providing one or more substrates selected from the group consisting of 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate, 5-hydroxyvalerate, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate and other longer chain 3-hydroxyacids containing seven or more carbons,

wherein the biological system expresses enzymes selected from the group consisting polyhydroxyalkanoate synthase, acyl-CoA transferase, hydroxyacyl CoA transferase, and hydroxyacyl CoA synthetase such that the polymers accumulate.

2. The polymer of claim 1 selected from the group consisting of poly(3-hydroxybutyrate-co-4-hydroxyvalerate), poly(4-hydroxyvalerate), poly(3-hydroxypropionate-co-5-hydroxyvalerate), poly(2-hydroxybutyrate), poly(2-hydroxybutyrate-co-3-hydroxybutyrate), poly(3-hydroxypropionate), produced in a biological system selected from the group comprising bacteria, yeasts, fungi and plants, wherein the biological system expresses enzymes selected from the group consisting polyhydroxyalkanoate synthase, acyl-CoA transferase and hydroxyacyl CoA transferase, and hydroxyacyl CoA synthetase such that the polymers accumulate in the presence of appropriate substrates.

3. The polymer of claim 1 wherein the polymer is poly(3-hydroxybutyrate-co-4-hydroxyvalerate).

4. The polymer of claim 1 wherein the polymer is poly(4-hydroxyvalerate).

5. The polymer of claim 1 wherein the polymer is poly(3-hydroxypropionate-co-5-hydroxyvalerate).

6. The polymer of claim 1 wherein the polymer is poly(3-hydroxypropionate).

7. A polyhydroxyalkanoate polymer comprising 2-hydroxybutyrate as a comonomer, wherein the polymer is produced in a biological system selected from the group comprising bacteria, yeasts, fungi and plants, wherein the biological system expresses enzymes selected from the

group consisting polyhydroxyalkanoate synthase, acyl-CoA transferase, hydroxyacyl CoA transferase, and hydroxyacyl CoA synthetase such that the polymers accumulate in the presence of appropriate substrates.

8. The polymer of claim 7 wherein the polymer is poly(2-hydroxybutyrate).

9. The polymer of claim 7 wherein the polymer is poly(2-hydroxybutyrate-co-3-hydroxybutyrate).

10. A method for making polymers in a biological system comprising

providing one or more substrates selected from the group consisting of 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate, 5-hydroxyvalerate, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate and other longer chain 3-hydroxyacids containing seven or more carbons,

wherein the biological system expresses enzymes selected from the group consisting polyhydroxyalkanoate synthase, acyl-CoA transferase, hydroxyacyl CoA transferase, and hydroxyacyl CoA synthetase such that the polymers accumulate.

11. The method of claim 10 wherein the organisms express one or more heterologous genes encoding the enzymes.

12. The method of claim 10 for making a copolymer of 3-hydroxybutyrate and 4-hydroxybutyrate comprising incubating equimolar amounts of (*R*)-3-hydroxybutyrate and 4-hydroxybutyrate with 4-hydroxybutyrate CoA transferase.




Figure 1 Pathways from levulinic acid to poly-4-hydroxyvalerate.

2/2

FIGURE 2





FIGURE 3



SEQUENCE LISTING

<110> Metabolix, Inc.

<120> Polyhydroxyalkanoate Biopolymer Compositions

<130> MBX 027 PCT

<140> unknown

<141> 1999-05-21

<150> 60/086,396

<151> 1998-05-22

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer- orfz
5' AvrII

<220>

<221> misc_feature

<222> (1)..(49)

<223> oligonucleotide primer

<400> 1

tccccttagga ttcaggaggt ttttatggag tggaaagaga tatataaag 49

<210> 2

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer- orfz
3' SalI

<220>

<221> misc_feature

<222> (1)..(38)

<223> oligonucleotide primer

SEQUENCE LISTING

<110> Metabolix, Inc.

<120> Polyhydroxyalkanoate Biopolymer Compositions

<130> MBX 027 PCT

<140> unknown

<141> 1999-05-21

<150> 60/086,396

<151> 1998-05-22

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer- orfZ
5' AvrII

<220>

<221> misc_feature

<222> (1)..(49)

<223> oligonucleotide primer

<400> 1

tcccctagga ttcaggaggt ttttatggag tggaaagaga tatataaag

49

<210> 2

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer- orfZ
3' SalI

<220>

<221> misc_feature

<222> (1)..(38)


<223> oligonucleotide primer



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/52, 15/54, 15/70, 1/21, C08G 63/06, C12P 7/62		A2	(11) International Publication Number: WO 99/61624 (43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11417 (22) International Filing Date: 21 May 1999 (21.05.99)		(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/086,396 22 May 1998 (22.05.98) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant: METABOLIX, INC. [US/US]; 303 Third Street, Cambridge, MA 02142 (US).			
(72) Inventors: SKRALY, Frank, A.; Apartment 5, 39 Bay State Road, Boston, MA 02215 (US). PEOPLES, Oliver, P.; 27 Radcliffe Road, Arlington, MA 02474 (US).			
(74) Agent: PABST, Patreo, L.; Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).			

(54) Title: POLYHYDROXYALKANOATE BIOPOLYMER COMPOSITIONS



Pathways from levulinic acid to poly-4-hydroxyvalerate.

(57) Abstract

Several novel PHA polymer compositions produced using biological systems include monomers such as 3-hydroxybutyrate, 3-hydroxypropionate, 2-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4-hydroxyvalerate and 5-hydroxyvalerate. These PHA compositions can readily be extended to incorporate additional monomers including, for example, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 6-hydroxyhexanoate or other longer chain 3-hydroxyacids containing seven or more carbons. This can be accomplished by taking natural PHA producers and mutating through chemical or transposon mutagenesis to delete or inactivate genes encoding undesirable activities. Alternatively, the strains can be genetically engineered to express only those enzymes required for the production of the desired polymer composition. Methods for genetically engineering PHA producing microbes are widely known in the art (Huisman and Madison, 1998, Microbiology and Molecular Biology Reviews, 63: 21-53). These polymers have a variety of uses in medical, industrial and other commercial areas.